Comparison of Immunological and virological response to cART between HIV-1/O and HIV-1/M patients followed-up in France: the ANRS ORIVAO and COPANA studies

被引：0
|
作者：
Unal, G. [1 ]
Seng, R. [2 ,3 ]
Alessandri-Gradt, E. [1 ]
Plessis, L. [2 ,3 ]
Leoz, M. [4 ]
Lefevre, C. [1 ]
Plantier, J-C [1 ]
Meyer, L. [2 ,3 ]
机构：
[1] Normandie Univ, Rouen Univ Hosp, UNIROUEN, GRAM 20,UNICAENDept Virol, Rouen, France
[2] Univ Paris Sud, Fac Med Paris Sud, Paris, France
[3] Univ Paris Saclay, CESP, Ctr Rech Epidemiol & Sante Populat, INSERM,U 1018, Le Kremlin Bicetre, France
[4] Normandie Univ, UNIROUEN, UNICAEN, GRAM 20, Rouen, France
来源：
HIV MEDICINE | 2019年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
PE31/2
引用
收藏
页码：267 / 267
页数：1
相关论文
共 50 条
  • [31] Highly frequent HIV-1 minority resistant variants at baseline of the ANRS 139 TRIO trial had a limited impact on virological response
    Charpentier, Charlotte
    Lee, Guinevere Q.
    Rodriguez, Christophe
    Visseaux, Benoit
    Storto, Alexandre
    Fagard, Catherine
    Molina, Jean-Michel
    Katlama, Christine
    Yazdanpanah, Yazdan
    Harrigan, P. Richard
    Descamps, Diane
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2015, 70 (07) : 2090 - 2096
  • [32] Prevalence of drug resistant mutants and virological response to combination therapy in patients with primary HIV-1 infection
    Tamalet, C
    Pasquier, C
    Yahi, N
    Colson, P
    Poizot-Martin, I
    Lepeu, G
    Gallais, H
    Massip, P
    Puel, J
    Izopet, J
    JOURNAL OF MEDICAL VIROLOGY, 2000, 61 (02) : 181 - 186
  • [33] REDUCED CAPACITY OF ANTIBODIES FROM PATIENTS INFECTED WITH HIV-1 GROUP-O TO NEUTRALIZE PRIMARY ISOLATES OF HIV-1 GROUP-M VIRUSES
    NYAMBI, P
    NKENGASONG, J
    PEETERS, M
    SIMON, F
    EBERLE, J
    JANSENS, W
    FRANSEN, K
    WILLEMS, B
    VEREECKEN, K
    HEYNDICKX, L
    PIOT, P
    VANDERGROEN, G
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 1995, 11 : S150 - S150
  • [34] Virological and clinical settings associated with HBV seroreversion and reactivation in HIV-1 infected patients in South-Eastern France
    Colson, P.
    Motte, A.
    Menard, A.
    Moreau, J.
    Ravaux, I.
    Poizot-Martin, I.
    Benhaim, S.
    Mokhtari, S.
    Gerolami, R.
    Tamalet, C.
    JOURNAL OF HEPATOLOGY, 2008, 48 : S78 - S79
  • [35] Immunological and virological factors at baseline may predict response to structured therapy interruption in early stage chronic HIV-1 infection
    García, F
    Plana, M
    Mestre, G
    Arnedo, M
    Gil, C
    Miró, JM
    Cruceta, A
    Pumarola, T
    Gallart, T
    Gatell, JM
    AIDS, 2002, 16 (13) : 1761 - 1765
  • [36] Results from a recently unblinded phase II trial (STIR-2102) evaluating HIV-1 immunogen administered to patients with HIV-1 chronic infection:: Impact on immunological responses and virological supression.
    Fernandez-Cruz, E
    Navarro, J
    Abad, ML
    Díaz, L
    Cantó, C
    Carbone, J
    Rodriguez, C
    Muñoz-Fernandez, MA
    Moreno, S
    Clotet, B
    Perez-Molina, J
    Peña, JM
    Gatell, JM
    Podzamczer, D
    Gonzalez-Lahoz, J
    CLINICAL IMMUNOLOGY, 2002, 103 (03) : S77 - S77
  • [37] Effect of dolutegravir functional monotherapy on HIV-1 virological response in integrase strand transfer inhibitor resistant patients
    Naeger, Lisa K.
    Harrington, Patrick
    Komatsu, Takashi
    Deming, Damon
    ANTIVIRAL THERAPY, 2016, 21 (06) : 481 - 488
  • [38] Comparison of HIV-1 viral load assay performance in immunological stable patients with low or undetectable viremia
    Gudrun Naeth
    Robert Ehret
    Frank Wiesmann
    Patrick Braun
    Heribert Knechten
    Annemarie Berger
    Medical Microbiology and Immunology, 2013, 202 : 67 - 75
  • [39] Comparison of HIV-1 viral load assay performance in immunological stable patients with low or undetectable viremia
    Naeth, Gudrun
    Ehret, Robert
    Wiesmann, Frank
    Braun, Patrick
    Knechten, Heribert
    Berger, Annemarie
    MEDICAL MICROBIOLOGY AND IMMUNOLOGY, 2013, 202 (01) : 67 - 75
  • [40] HIV-1 genotype and phenotype correlate with virological response to abacavir, amprenavir and efavirenz in treatment-experienced patients
    Falloon, J
    Ait-Khaled, M
    Thomas, DA
    Brosgart, CL
    Eron, JJ
    Feinberg, J
    Flanigan, TP
    Hammer, SM
    Kraus, PW
    Murphy, R
    Torres, R
    Masur, H
    AIDS, 2002, 16 (03) : 387 - 396
12345